2-乙基-3-甲氧基苯甲酸甲酯 | 108593-43-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-乙基-3-甲氧基苯甲酸甲酯
• 英文名称: 2-Ethyl-3-methoxybenzoesaeure-methylester
• 英文别名: 2-ethyl-3-methoxy-benzoic acid methyl ester；2-Aethyl-3-methoxy-benzoesaeure-methylester；Methyl 2-ethyl-3-methoxybenzoate
• CAS: 108593-43-7
• 化学式: C₁₁H₁₄O₃
• 分子量: 194.23
• InChiKey: DJVXOULKAVLWCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-乙基-3-甲氧基苯甲酸甲酯 在 乙醇 、 肼 作用下， 生成 2-ethyl-3-methoxy-benzoic acid hydrazide
  参考文献：
  名称：

  Richtzenhain; Meyer-Delius, Chemische Berichte, 1948, vol. 81, p. 81,89

  摘要：

  DOI：
• 作为产物：
  描述：

  甲醇 、 2-乙基-3-甲氧基苯甲酸 在 硫酸 作用下， 生成 2-乙基-3-甲氧基苯甲酸甲酯
  参考文献：
  名称：

  Richtzenhain; Meyer-Delius, Chemische Berichte, 1948, vol. 81, p. 81,89

  摘要：

  DOI：

文献信息

• Enantioselective Synthesis of <i>cis</i>‐Decalins by Merging the Birch Reduction and Inverse‐Electron‐Demand Diels–Alder Reaction
  作者：Xu‐Ge Si、Shi‐Xiong Feng、Zhuo‐Yan Wang、Xiaoyu Chen、Meng‐Meng Xu、Yu‐Zhen Zhang、Jun‐Xiong He、Limin Yang、Quan Cai

  DOI：10.1002/anie.202303876

  日期：2023.8.7

  Asymmetric synthesis of highly functionalized chiral cis-decalins was realized by merging Birch reduction and a tandem olefin migration/asymmetric IEDDA reaction. Up to six contiguous and two quaternary stereocenters could be formed in one step by efficient kinetic resolution. The synthetic value of the approach is illustrated by the concise total synthesis of (+)-occidentalol and the synthesis of

  通过合并 Birch 还原和串联烯烃迁移/不对称 IEDDA 反应，实现了高功能化手性顺式十氢化萘的不对称合成。通过有效的动力学拆分，一步可以形成多达六个连续的和两个四元立构中心。(+)-occidentalol的简明全合成和七种三萜关键中间体的合成说明了该方法的合成价值。
• Heteroaryl sulfonamides and CCR2
  申请人：ChemoCentryx, Inc.

  公开号：EP2474532A1

  公开（公告）日：2012-07-11

  A compound of the formula (I), or a salt thereof: where Ar is selected from the group consisting of substituted or unsubstituted C6-10 aryl and substituted or unsubstituted 5- to 10-membered heteroaryl; R1 is selected from the group consisting of hydrogen, unsubstituted C1 alkyl, substituted or unsubstituted C3-8 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, and substituted or unsubstituted 3- to 10-membered heterocyclyl; Y1 is selected from the group consisting of -CR2a-, -N-, and -N+(O)--; Y2 is selected from the group consisting of -CR2b-, -N-, and -N+(O)--; Y3 is selected from the group consisting of -CR2c-, -N-, and -N+(O)--; R2a, R2b, and R2c are each independently selected from the group consisting of hydrogen, halogen, -CN, -C(O)R3, -CO2R3, -C(O)NR3R4, -OR3, - OC(O)R3, -OC(O)NR3R4, -SR3, -S(O)R3, -S(O)2R3, -S(O)2NR3R4, -NO2, -NR3R4, -NR3C(O)R4, -NR3C(O)OR4, -NR3S(O)2R4, -NR3C(O)NR4R5, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl; R3, R4, and R5 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl; R3 and R4, R4 and R5 or R3 and R5 may, together with the atoms to which they are attached, form a substituted or unsubstituted 5-, 6-, or 7-membered ring; Y4 is selected from the group consisting of -N- and -N+(O)--; L is selected from the group consisting of a bond, -O-, -S-, -S(O)-, S(O)2-, - CR6R7-, -NR8-, -C(O)- and -NR8C(O)-; R6 and R7 are each independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, -CN, -OR9, -NR10R11, -S(O)R9, and -S(O)2R9; R6 and R7 may, together with the carbon atom to which they are attached, form substituted or unsubstituted C3-8 cycloalkyl or substituted or unsubstituted 3-to 10-membered heterocyclic ring; R9 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, and substituted or unsubstituted 3- to 10-membered heterocyclyl; R10 and R11 are each independently selected from the group consisting of substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted C2-8 alkenyl, and substituted or unsubstituted C2-8 alkynyl; R10 and R11 of -NR10R11 may, together with the nitrogen, form a substituted or unsubstituted C3-8 cycloalkyl or substituted or unsubstituted 3- to 10-membered heterocyclyl; R8 is selected from the group consisting of hydrogen, C(O)R12, S(O)2R12, CO2R12, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C2-6 alkenyl, and substituted or unsubstituted C2-6 alkynyl; R12 is selected from the group consisting of substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-6 alkenyl, substituted or unsubstituted C2-6 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, and substituted or unsubstituted 5- to 10-membered heteroaryl; Z1 is selected from the group consisting of substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted 3- to 10-membered heterocyclyl, and -NR13R14; R13 and R14 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted C2-8 alkenyl, substituted or unsubstituted C2-8 alkynyl, substituted or unsubstituted 3- to 10-membered heterocyclyl, substituted or unsubstituted C6-10 aryl, substituted or unsubstituted 5- to 10-membered heteroaryl, substituted or unsubstituted (C1-4 alkyl)-(C6-10 aryl), and substituted or unsubstituted (C1-4 alkyl)-(5- to 10-membered heteroaryl); R13 and R14 may, together with the nitrogen, form a substituted or unsubstituted 4-, 5-, 6-, or 7-membered heterocyclyl with the proviso that compounds of formula CC are excluded: where X14 is selected from the group consisting of -Cl, -NO2, -OCH3, -CH3, - NHC(O)CH3, and -CH2CH2-(phenyl); R65 is selected from the group consisting of hydrogen, substituted or unsubstituted C1-4 alkyl, and substituted or unsubstituted -SO2(phenyl); and R60 is selected from the group consisting of -NR61CH2CH2OR62, - NR61CH2CH2NR63R64, -NR61CH2CH2SR62, where R61 is selected from the group consisting of hydrogen and substituted or unsubstituted phenyl; R62 is selected from the group consisting of substituted or unsubstituted phenyl, and substituted or unsubstituted C1-4 alkyl; and R63 and R64 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C1-8 alkyl, substituted or unsubstituted phenyl, substituted or unsubstituted -SO2(phenyl), - C(O)CH3, -C(O)C(O)OH, and -C(O)2C(CH3)3.

  一种具有式(I)或其盐的化合物：其中，Ar选自被取代或未取代的C6-10芳基或被取代或未取代的5-至10元杂芳基；R1选自氢、未取代的C1烷基、被取代或未取代的C3-8烷基、被取代或未取代的C2-6烯基、被取代或未取代的C2-6炔基和被取代或未取代的3-至10元杂环基；Y1选自-CR2a-、-N-和-N+(O)-；Y2选自-CR2b-、-N-和-N+(O)-；Y3选自-CR2c-、-N-和-N+(O)-；R2a、R2b和R2c各自独立地选自氢、卤素、-CN、-C(O)R3、-CO2R3、-C(O)NR3R4、-OR3、-OC(O)R3、-OC(O)NR3R4、-SR3、-S(O)R3、-S(O)2R3、-S(O)2NR3R4、-NO2、-NR3R4、-NR3C(O)R4、-NR3C(O)OR4、-NR3S(O)2R4、-NR3C(O)NR4R5、被取代或未取代的C1-8烷基、被取代或未取代的C2-8烯基、被取代或未取代的C2-8炔基、被取代或未取代的3-至10元杂环基、被取代或未取代的C6-10芳基和被取代或未取代的5-至10元杂芳基；R3、R4和R5各自独立地选自氢、被取代或未取代的C1-8烷基、被取代或未取代的C2-8烯基、被取代或未取代的C2-8炔基、被取代或未取代的C6-10芳基、被取代或未取代的5-至10元杂芳基和被取代或未取代的3-至10元杂环基；R3和R4、R4和R5或R3和R5可与它们所连接的原子一起形成被取代或未取代的5-、6-或7元环；Y4选自-N-和-N+(O)-；L选自键、-O-、-S-、-S(O)-、S(O)2-、-CR6R7-、-NR8-、-C(O)-和-NR8C(O)-；R6和R7各自独立地选自氢、卤素、被取代或未取代的C1-8烷基、被取代或未取代的3-至10元杂环基、被取代或未取代的C2-6烯基、被取代或未取代的C2-6炔基、-CN、-OR9、-NR10R11、-S(O)R9和-S(O)2R9；R6和R7可与它们所连接的碳原子一起形成被取代或未取代的C3-8环烷基或被取代或未取代的3-至10元杂环基；R9选自氢、被取代或未取代的C1-8烷基、被取代或未取代的C2-8烯基、被取代或未取代的C2-8炔基、被取代或未取代的C6-10芳基、被取代或未取代的5-至10元杂芳基和被取代或未取代的3-至10元杂环基；R10和R11各自独立地选自被取代或未取代的C1-8烷基、被取代或未取代的3-至10元杂环基、被取代或未取代的C6-10芳基、被取代或未取代的5-至10元杂芳基、被取代或未取代的C2-8烯基和被取代或未取代的C2-8炔基；-NR10R11中的R10和R11可与氮一起形成被取代或未取代的C3-8环烷基或被取代或未取代的3-至10元杂环基；R8选自氢、C(O)R12、S(O)2R12、CO2R12、被取代或未取代的C1-8烷基、被取代或未取代的3-至10元杂环基、被取代或未取代的C2-6烯基和被取代或未取代的C2-6炔基；R12选自被取代或未取代的C1-8烷基、被取代或未取代的C2-6烯基、被取代或未取代的C2-6炔基、被取代或未取代的3-至10元杂环基、被取代或未取代的C6-10芳基和被取代或未取代的5-至10元杂芳基；Z1选自被取代或未取代的C6-10芳基、被取代或未取代的5-至10元杂芳基、被取代或未取代的3-至10元杂环基和-NR13R14；R13和R14各自独立地选自氢、被取代或未取代的C1-8烷基、被取代或未取代的C2-8烯基、被取代或未取代的C2-8炔基、被取代或未取代的3-至10元杂环基、被取代或未取代的C6-10芳基、被取代或未取代的5-至10元杂芳基、被取代或未取代的(C1-4烷基)-(C6-10芳基)和被取代或未取代的(C1-4烷基)-(5-至10元杂芳基)；R13和R14可与氮一起形成被取代或未取代的4-、5-、6-或7元杂环基；其中排除式CC的化合物：其中，X14选自-Cl、-NO2、-OCH3、-CH3、-NHC(O)CH3和-CH2CH2-(苯基)；R65选自氢、被取代或未取代的C1-4烷基和被取代或未取代的-SO2(苯基)；R60选自-NR61CH2CH2OR62、-NR61CH2CH2NR63R64和-NR61CH2CH2SR62；其中，R61选自氢和被取代或未取代的苯基；R62选自被取代或未取代的苯基和被取代或未取代的C1-4烷基；R63和R64各自独立地选自氢、被取代或未取代的C1-8烷基、被取代或未取代的苯基、被取代或未取代的-SO2(苯基)、-C(O)CH3、-C(O)C(O)OH和-C(O)2C(CH3)3。
• Effenberger, Franz; Ziegler, Thomas, Chemische Berichte, 1987, vol. 120, p. 1339 - 1346
  作者：Effenberger, Franz、Ziegler, Thomas

  DOI：——

  日期：——
• EFFENBERGER, FRANZ;ZIEGLER, THOMAS, CHEM. BER., 120,(1987) N 8, 1339-1346
  作者：EFFENBERGER, FRANZ、ZIEGLER, THOMAS

  DOI：——

  日期：——
• [EN] ESTROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS DE RECEPTEUR D'OESTROGENES
  申请人：MERCK & CO INC

  公开号：WO2004073612A2

  公开（公告）日：2004-09-02

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget s disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer.